IgG antibodies are frequently utilized to treat cancer. They are being explored as a potential substitute for radiation and chemotherapy since they support the body's immune system in its fight against cancer. A group of scientists is investigating a novel kind of antibody that may halt the growth of ovarian and breast cancer tumors that do not respond to treatment by targeting cancer cells by stimulating the immune system.
This antibody will cure cancer
IgG is an antibody that is frequently utilized in immunotherapy to treat cancer. It aids the body's defenses against cancer and is being explored as a potential substitute for radiation and chemotherapy. Some individuals, particularly those with HER2-associated breast and ovarian malignancies, do not respond well to this treatment, and occasionally the body becomes immune to it.
London scientists did research
To solve this issue, researchers at King's college london studied an alternative antibody known as IgE. Unlike IgG, this antibody stimulates the immune system differently. IgE antibodies activate the body's immune cells that surround the tumor but are often dormant. cancer cells are specifically targeted by this.
This thing came out in research
Rather than using IgG antibodies, the researchers made and examined IgE antibodies. IgE slowed down tumor growth in mice and triggered the immune system against HER2-affected cancer cells, according to Dr. Heather Bax, a researcher at King's college London. Mice that do not react to conventional treatment acquired this tumor. This suggests that patients for whom current treatments are ineffective may benefit from this novel approach.
These cancer patients will benefit
Subsequent research revealed that IgE antibodies could reawaken the immune system surrounding the tumor. This strengthens the immune system's defenses against cancer. The Journal for Immunotherapy of cancer (JITC) has published this study. About 20% of ovarian and breast tumors include a marker known as HER2, according to Dr. Heather Bax.
We discovered that HER2 can trigger the immune system in a novel manner after producing IgE antibodies against it. This can efficiently target HER2 cancer cells, particularly when current treatments are ineffective. She added that individuals with HER2 cancer may now have a new therapy option thanks to this new discovery.
This antibody will cure cancer
IgG is an antibody that is frequently utilized in immunotherapy to treat cancer. It aids the body's defenses against cancer and is being explored as a potential substitute for radiation and chemotherapy. Some individuals, particularly those with HER2-associated breast and ovarian malignancies, do not respond well to this treatment, and occasionally the body becomes immune to it.
London scientists did research
To solve this issue, researchers at King's college london studied an alternative antibody known as IgE. Unlike IgG, this antibody stimulates the immune system differently. IgE antibodies activate the body's immune cells that surround the tumor but are often dormant. cancer cells are specifically targeted by this.
This thing came out in research
Rather than using IgG antibodies, the researchers made and examined IgE antibodies. IgE slowed down tumor growth in mice and triggered the immune system against HER2-affected cancer cells, according to Dr. Heather Bax, a researcher at King's college London. Mice that do not react to conventional treatment acquired this tumor. This suggests that patients for whom current treatments are ineffective may benefit from this novel approach.
These cancer patients will benefit
Subsequent research revealed that IgE antibodies could reawaken the immune system surrounding the tumor. This strengthens the immune system's defenses against cancer. The Journal for Immunotherapy of cancer (JITC) has published this study. About 20% of ovarian and breast tumors include a marker known as HER2, according to Dr. Heather Bax.
We discovered that HER2 can trigger the immune system in a novel manner after producing IgE antibodies against it. This can efficiently target HER2 cancer cells, particularly when current treatments are ineffective. She added that individuals with HER2 cancer may now have a new therapy option thanks to this new discovery.
click and follow Indiaherald WhatsApp channel